CCR8 is a new therapeutic target in cutaneous T-cell lymphomas

J erôme Giustiniani, Gabor Dobos, H el ene Moins-Teisserenc, Tiago Eustaquio, Maxime Battistella, Nicolas Ortonne, Caroline Ram-Wolff, Jean-David Bouaziz, Anne Marie-Cardine, Samia Mourah, Martine Bagot, Thomas S. Kupper, Rachael A. Clark, Armand Bensussan,* and Ad ele de Masson* INSERM, U955, Henri Mondor Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP), Universit e Paris Est Cr eteil, Cr eteil, France; Department of Dermatology, AP-HP, Saint Louis Hospital, Paris, France; Institut de Recherche Saint-Louis, Universit e de Paris, Paris, France; INSERM, UMR 976 “Human Immunology, Pathophysiology and Immunotherapy,” Paris, France; Department of Dermatology, Charit e Hospital, Berlin, Germany; INSERM, Unit e Mixte de Recherche 1160, Paris, France; Department of Hematology, AP-HP, Saint Louis Hospital, Paris, France; Department of Pathology, AP-HP, Saint Louis Hospital, Paris, France; Department of Pathology, Henri Mondor Hospital, AP-HP, Paris, France; Department of Tumor Genomics and Pharmacology, AP-HP, Saint Louis Hospital, Paris, France; and Department of Dermatology, Dana Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA

[1]  N. Siemers,et al.  Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models , 2021, Cancer Research.

[2]  M. Bagot,et al.  Mogamulizumab-induced vitiligo in patients with Sézary syndrome: three cases , 2021, European Journal of Dermatology.

[3]  J. Cayuela,et al.  Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker , 2020, The British journal of dermatology.

[4]  H. Kohrt,et al.  Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Conway,et al.  Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors , 2019, Clinical Cancer Research.

[6]  B. Janela,et al.  Identification of CD39 as a Marker for the Circulating Malignant T-Cell Clone of Sézary Syndrome Patients. , 2019, The Journal of investigative dermatology.

[7]  R. Clark,et al.  Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma. , 2019, JCI insight.

[8]  M. Bagot,et al.  Association of autoimmunity and long‐term complete remission in patients with Sézary syndrome treated with mogamulizumab , 2018, The British journal of dermatology.

[9]  C. Elmets,et al.  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. , 2018, The Lancet. Oncology.

[10]  K. Ladell,et al.  CCR8 Expression Defines Tissue-Resident Memory T Cells in Human Skin , 2018, The Journal of Immunology.

[11]  A. Janin,et al.  KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. , 2017, Blood.

[12]  A. Kossenkov,et al.  TIGIT and Helios Are Highly Expressed on CD4+ T Cells in Sézary Syndrome Patients. , 2017, The Journal of investigative dermatology.

[13]  G. Plitas,et al.  Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. , 2016, Immunity.

[14]  K. Yanagihara,et al.  Molecular analysis of loss of CCR4 expression during mogamulizumab monotherapy in an adult T cell leukemia/lymphoma patient , 2015, Annals of Hematology.

[15]  D. Sasseville,et al.  The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL) , 2015, Clinical Cancer Research.

[16]  M. Goswami,et al.  Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sézary Syndrome , 2014, Clinical Cancer Research.

[17]  K. Uchimaru,et al.  Loss of CCR4 antigen expression after mogamulizumab therapy in a case of adult T‐cell leukaemia‐lymphoma , 2013, British journal of haematology.

[18]  J. Karbach,et al.  Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans , 2013, Proceedings of the National Academy of Sciences.

[19]  R. Mansel,et al.  Epidermis instructs skin homing receptor expression in human T cells. , 2012, Blood.

[20]  R. Clark,et al.  Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients , 2012, Science Translational Medicine.

[21]  D. Sasseville,et al.  Transcriptional Profiles Predict Disease Outcome in Patients with Cutaneous T-Cell Lymphoma , 2010, Clinical Cancer Research.

[22]  R. Biassoni,et al.  CD4(+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor. , 2001, Blood.

[23]  L. Michel,et al.  CD158k is a reliable marker for diagnosis of Sézary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells. , 2015, The Journal of investigative dermatology.